Clinical trial
An Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine Tumors
NCT05077384 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine Tumors
- Lead sponsor
- Hutchmed
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 2, 2021
- Completion date
- January 17, 2025
- Enrollment
- 36 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
neuroendocrine tumors, non-hematologic malignancy